These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30765144)

  • 1. Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy.
    Vitale I; Sistigu A; Manic G; Rudqvist NP; Trajanoski Z; Galluzzi L
    Trends Cell Biol; 2019 May; 29(5):396-416. PubMed ID: 30765144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing neoantigens for personalized cancer immunotherapy.
    Capietto AH; Jhunjhunwala S; Delamarre L
    Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cancer immunotherapy targeting neoantigens derived from tumor-specific gene mutations].
    Sasada T
    Nihon Rinsho; 2017 Feb; 75(2):189-195. PubMed ID: 30562851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
    Sun Z; Chen F; Meng F; Wei J; Liu B
    Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing neoantigen-targeted T cell-based treatments for solid tumors.
    Yamamoto TN; Kishton RJ; Restifo NP
    Nat Med; 2019 Oct; 25(10):1488-1499. PubMed ID: 31591590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.
    Chabanon RM; Pedrero M; Lefebvre C; Marabelle A; Soria JC; Postel-Vinay S
    Clin Cancer Res; 2016 Sep; 22(17):4309-21. PubMed ID: 27390348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigens in cancer immunotherapy.
    Schumacher TN; Schreiber RD
    Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads.
    Lussier DM; Alspach E; Ward JP; Miceli AP; Runci D; White JM; Mpoy C; Arthur CD; Kohlmiller HN; Jacks T; Artyomov MN; Rogers BE; Schreiber RD
    Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34099555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Landscape of Tumor Antigens in T Cell Immunotherapy.
    Ilyas S; Yang JC
    J Immunol; 2015 Dec; 195(11):5117-22. PubMed ID: 26589749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preface: More than two decades of modern tumor immunology.
    Galluzzi L; Rudqvist NP
    Methods Enzymol; 2020; 632():xxiii-xlii. PubMed ID: 32000917
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting neoantigens to augment antitumour immunity.
    Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
    Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
    Ward JP; Gubin MM; Schreiber RD
    Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-expression profiling to predict responsiveness to immunotherapy.
    Jamieson NB; Maker AV
    Cancer Gene Ther; 2017 Mar; 24(3):134-140. PubMed ID: 27834354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of shared neoantigens in prevalent mutations in cancer.
    Ragone C; Cavalluzzo B; Mauriello A; Tagliamonte M; Buonaguro L
    J Transl Med; 2024 Apr; 22(1):344. PubMed ID: 38600547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer.
    Alvarado-Cruz I; Meas R; Paluri SLA; Carufe KEW; Khan M; Sweasy JB
    Mutagenesis; 2020 Feb; 35(1):69-78. PubMed ID: 31880305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Neoantigens.
    Schumacher TN; Scheper W; Kvistborg P
    Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.
    Sensi M; Anichini A
    Clin Cancer Res; 2006 Sep; 12(17):5023-32. PubMed ID: 16951217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.